Comparing the current results to its competitors, Teva Pharmaceutical Industries Limited reported Revenue decrease in the 2 quarter 2026 year on year by -0.81 %, despite the revenue increase by the most of its competitors of 12.69 %, recorded in the same quarter.
Teva Pharmaceutical Industries Limited, slower than the average decrease reported by the company's competitors of -6.13 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -6.13 %
Teva Pharmaceutical Industries Limited's Comment on Competition and Industry Peers
UZEDY competes with multiple products in the treatment of multiple sclerosis (MS) in the United States and Europe, including COPAXONE (glatiramer acetate injection), whose market share declined in 2025 due to new treatments. BENDEKA, a liquid infusion formulation of bendamustine hydrochloride licensed from Eagle, faces direct competition from Belrapzo, a ready-to-dilute bendamustine hydrochloride product from Eagle, and Vivimusta, a bendamustine hydrochloride injection from Azurity Pharmaceuticals. Additional competitors to BENDEKA include combination therapies for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as newer targeted oral therapies. The generic pharmaceutical market is competitive, with increased FDA approvals for generic products contributing to price competition and margin pressures. In Europe, competition is intense regarding pricing, quality, customer service, and portfolio relevance. The company maintains a pan-European presence, whereas most European competitors focus on limited markets or business lines. In international markets, competition includes local generic companies competing on pricing, time to market, reputation, and customer service. The biosimilars business is also highly competitive as intellectual property protections expire in the United States. Competitors identified include Azurity Pharmaceuticals, COPAXONE, and Eagle.
October 3, 2024
In a significant move that underscores the ever-evolving landscape of cancer treatment, Teva Pharmaceuticals International GmbH and mAbxience have announced an expanded strategic partnership with a new global licensing agreement aimed at developing an innovative anti PD-1 oncology biosimilar candidate. This exciting collaboration builds upon the companies’ initial partnership formed in April 2024, epitomizing a commitment to enhancing patient access to vital therapies in the oncology space.The agreement represents a pivotal shift in the biosimilars market, where the demand for effective and accessible cancer therapies continues to grow. As one of the primary therapeutic options for treating various cancers...
Publicly Traded Peers of Teva Pharmaceutical Industries Limited
Biofrontera Inc Share Performance
-22.88%
30 Days
Biofrontera Inc
Profile
Biofrontera Inc is a pharmaceutical company that specializes in developing and commercializing dermatological treatments for various skin conditions. Their business model revolves around research and development to create innovative products, obtaining regulatory approvals, and marketing and selling their products globally through direct sales teams and distribution partnerships. They aim to provide patients with effective and safe dermatological treatments while generating revenues through product sales.
Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Sources:
Teva Pharmaceutical Industries Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Teva Pharmaceutical Industries Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
